Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prilosec

This article was originally published in The Tan Sheet

Executive Summary

Manhattan federal judge rejects AstraZeneca assertion generic omeprazole would infringe patent for active metabolites of Prilosec. '499 patent encompasses synthetic sulphenamides only, not those produced through in vivo conversion of omeprazole, court concludes May 29. Rulings on three antibiotic-related Prilosec patents expected in August in AstraZeneca's ongoing litigation against four generic firms. Basic omeprazole patent expires in October. Last year, two FDA advisory committees voted against OTC episodic heartburn relief indication for Prilosec but left open possibility of a chronic heartburn indication
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS092630

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel